AMPK: a novel target controlling inflammation.
- Author:
Feng YAO
1
;
Guang-Yan JI
;
Li ZHANG
Author Information
1. Department of Pathophysiology, Chongqing Medical University, Chongqing, China.
- Publication Type:Journal Article
- MeSH:
AMP-Activated Protein Kinases;
metabolism;
Homeostasis;
Inflammation;
enzymology;
Metformin;
pharmacology;
NF-kappa B;
antagonists & inhibitors;
Phosphorylation
- From:
Acta Physiologica Sinica
2012;64(3):341-345
- CountryChina
- Language:Chinese
-
Abstract:
The AMP-activated protein kinase (AMPK) is a pivotal serine/threonine kinase participating in the regulation of glucose, lipid as well as protein metabolism and maintenance of energy homeostasis. Recent studies demonstrated that AMPK can also inhibit nuclear factor-κB, suppress the expression of inflammatory genes and attenuate inflammatory injury through phosphorylating its downstream targets including SIRT1, PGC-lα, p53 and FoxO3a. In addition, the widely used antidiabetic metformin also exerts its anti-inflammatory effects through activating AMPK. Therefore, AMPK is emerging as a promising novel target for the development of anti-inflammatory drugs. This review summarized the anti-inflammatory effects of AMPK and the underling molecular mechanisms.
